Prostate cancer is a significant health problem in the United States and is the focus of increasing attention in our society. With the aging of the US population, it is likely that prostate cancer will continue to grow in importance. The options for systemic therapy of metastatic prostate cancer should be familiar to physicians, including nonspecialists, whose patients seek their advice and counsel.
Methods
Past and recent literature was surveyed to provide an understanding of the systemic treatment of advanced prostate cancer. The author presents a review of the systemic treatment of metastatic prostate cancer in different clinical circumstances and addresses the current status of chemotherapy in the management of advanced prostate cancer.
Results
Early androgen deprivation used over prolonged periods appears to be modestly superior to delayed androgen deprivation with a small potential survival advantage and an advantage in delaying disease progression in advanced prostate cancer. Patients with hormone-refractory prostate cancer may benefit from secondary hormonal therapy (eg, adrenal enzyme inhibitors, antiandrogens, glucocorticoids) and chemotherapy.
Conclusions
The choices of therapy for metastatic prostate cancer depend on individual patient preference. Patients and physicians should be aware of the possible side effects associated with the therapeutics options for treatment of metastatic prostate cancer.
Get full access to this article
View all access options for this article.
References
1.
LandisS.H., MurrayT., BoldenS.Cancer statistics, 1998. CA Cancer J Clin.1998; 48: 6–29.
2.
CrawfordE.D., EisenbergerM.A., McLeodD.G.A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med.1989; 321: 419–424.
3.
ByarD.P.Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer.1973; 32: 1126–1130.
4.
CassilethB.R., SolowayM.S., VogelzangN.J.Patients’ choice of treatment in stage D prostate cancer. Urology.1989; 33(suppl 5): 57–62.
5.
GoldenbergS.L., BruchovskyN., GleaveM.E.Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology.1995; 45: 839–845.
6.
OliverR.T., WilliamsG., ParisA.M.Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology.1997; 49: 79–82.
7.
FleshnerN.E., TrachtenbergJ.Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol.1995; 154: 1642–1646.
8.
LabrieF., DupontA., BelangerA.New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med.1982; 5: 267–275.
9.
Anonymous.Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate: results of NCI intergroup study 0105. J Urol.1997; 157(suppl 4): 336.
10.
DalesioO., van TinterenH., DenisL.Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet.1995; 346: 265–269.
11.
CaubetJ.F., TostesonT.D., DongE.W.Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology.1997; 49: 71–78.
12.
DijkmanG.A., JanknegtR.A., De ReijkeT.M.Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol.1997; 158: 160–163.
13.
DenisL.J., KeuppensF., SmithP.H.Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol.1998; 33: 144–151.
14.
GreenN., BodnerH., BrothE.Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys.1984; 10: 971–976.
15.
NegliaW.J., HusseyD.H., JohnsonD.E.Megavoltage radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys.1977; 2: 873–882.
16.
RayG.R., CassadyJ.R., BagshawM.A.Definitive radiation therapy of carcinoma of the prostate. A report on 15 years of experience. Radiology.1973; 106: 407–418.
17.
HarisiadisL., VeenemaR.J., SenyszynJ.J.Carcinoma of the prostate: treatment with external radiotherapy. Cancer.1978; 41: 2131–2142.
18.
ArcangeliG., SaracinoB., MicheliA.Radiotherapy with or without androgen deprivation in the treatment of localized adenocarcinoma of the prostate. Am J Clin Oncol.1998; 21: 1–5.
19.
BollaM., GonzalezD., WardeP.Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med.1997; 337: 295–300.
20.
PilepichM.V., CaplanR., ByhardtR.W.Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol.1997; 15: 1013–1021.
21.
GranforsT., ModigH., DamberJ.Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol.1998; 159: 2030–2034.
22.
ZagarsG.K., PollackA., von EschenbachA.C.Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patientsirradiated in the prostate specific antigen era. Cancer.1997; 79: 1370–1380.
23.
KramolowskyE.V.The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol.1988; 139: 1242–1244.
24.
ZinckeH.Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology.1989; 33(suppl 5): 27–36.
25.
deKernionJ.B., NeuwirthH., SteinA.Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J Urol.1990; 144: 700–703.
26.
ByarD.P., CorleD.K.Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. Monogr Natl Cancer Inst.1988; 7: 165–170.
27.
Anonymous.Immediate versus deferred treatment for advanced prostate cancer: initial results of the Medical Research Council trial. Br J Urol.1997; 79: 235–246.
28.
TaylorC.D., ElsonP., TrumpD.L.Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol.1993; 11: 2167–2172.
29.
HussainM., WolfM., MarshallE.Effect of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol.1994; 12: 1868–1875.
30.
KellyW.K., ScherH.I.Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol.1993; 149: 607–609.
31.
DupontA., GomezJ.L., CusanL.Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol.1993; 150: 908–913.
32.
WildingG., ChenM., GelmannE.P.Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate.1989; 14: 103–115.
33.
VeldscholteJ., Ris-StalpersC., KuiperG.G.A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun.1990; 173: 534–540.
34.
SmallE.J., SrinivasS.The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer.1995; 76: 1428–1434.
35.
SherH.I., KellyW.K.Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol.1993; 11: 1566–1572.
36.
DupontA., GomezJ.L., CusanL.Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol.1993; 150: 908–913.
37.
ScherH.I., ZhangZ.F., NanusD.Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology.1996; 47: 61–69.
38.
SmallE.J., SchellhammerP., VennerP.A double-blind assessment of antiandrogen withdrawal from casodex (C) or eulexin (E) therapy while continuing luteinizing hormone releasing hormone analog (LHRH-a) therapy for patients (pts) with stage D2 prostate cancer (PCA). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A658.
FowlerJ.E.Jr, PandeyP., SeaverL.E.Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol.1995; 154: 448–453.
41.
McLeodD.G., BensonR.C.Jr, EisenbergerM.A.The use of flutamide in hormone-refractory metastatic prostate cancer. Cancer.1993; 72: 3870–3873.
42.
KucukO., BlumensteinB., MoinpourC.Phase II trial of Casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipulation: a Southwest Oncology Group (SWOG) study (SWOG 9235). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A618.
43.
JoyceR., FentonM.A., RodeP.High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol.1998; 159: 149–153.
44.
SherH.I., LiebertzC., KellyW.K.Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol.1997; 15: 2928–2938.
45.
MuscatoJ.J., AhmannT.A., JohnsonK.M.Optimal dosing of ketoconazole and hydrocortisone (HC) leads to long responses in hormone-refractory prostate cancer. Proc Annu Meet Am Soc Clin Oncol.1994; 13: A701.
46.
SmallE.J., BaronA.D., FippinL.Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol.1997; 157: 1204–1207.
47.
SartorO., CooperM., WeinbergerM.Surprising activity of flutamide withdrawal when combined with aminoglutethimide, in treatment of “hormone-refractory” prostate cancer. J Natl Cancer Inst.1994; 86: 222–227.
48.
TannockI., GospodarowiczM., MeakinW.Treatment of metastatic prostate cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol.1989; 7: 590–597.
49.
MyersC., CooperM., SteinC.Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol.1992; 10: 881–889.
50.
KellyW.K., ScherH.I., MazumdarM.Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol.1993; 11: 607–615.
51.
ScottW.W., GibbonsR.P., JohnsonD.E.The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J Urol.1976; 116: 211–213.
52.
MurphyG.P., GibbonsR.P., JohnsonD.E.A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation. J Urol.1977; 118: 288–291.
53.
SlackN.H., BradyM.F., MurphyG.P.A re-examination of the stable category for evaluating response in patients with advanced prostate cancer. Cancer.1984; 54: 564–574.
54.
SchmidtJ.D., ScottW.W., GibbonsR.P.Comparison of procarbazine, imidazole-carboxamide, and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol.1979; 121: 185–189.
55.
LoeningS.A., ScottW.W., DeKernionJ.A comparison of hydroxyurea, methy-chloroethyl-cyclohexy-nitrosourea, and cyclophosphamide in patients with advanced carcinoma of the prostate. J Urol.1981; 125: 812–816.
56.
TortiF.M., AstonD., LumB.L.Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol.1983; 1: 477–482.
57.
TannockI.F., OsobaD., StocklerM.R.Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol.1996; 14: 1756–1764.
58.
KantoffP.W., ConawayM., WinerE.Hydrocortisone with or without mitoxantrone in patients with hormone-refractory prostate cancer: preliminary results from a prospective randomized CALGB study (9182) comparing chemotherapy to best supportive care. Proc Annu Meet Am Soc Clin Oncol.1996; 14: 1748.
59.
SmallE.J., MarshalM.E., ReynoL.Superiority of suramin and hydrocortisone over placebo and hydrocortisone: results of a multi-center double-blind phase III study in patients with hormone-refractory prostate cancer. Proc Annu Meet Am Soc Clin Oncol.1998; 17: 308.
